Clinical Trial Update: Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating recombinant human C1 esterase inhibitor to prevent contrast-induced nephropathy in high-risk subjects with acute kidney injury has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Recombinant human C1 esterase inhibitor (C1 esterase inhibitor (recombinant))

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Acute Kidney Injury | Phase 2 | Status: COMPLETED